Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track COCP with free AI briefings, catalyst countdowns, and dilution alerts.

COCP · Cocrystal Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.2M Cash on Hand
2.7mo Cash Runway
Follow COCP by email Get an email when COCP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about COCP, unsubscribe in one click. Privacy

📣 What COCP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CC-42344 Influenza A Phase 2 · NCT06160531 Completed
CDI-31244 Chronic Hepatitis C Phase 2 · NCT03501550 Completed
CDI-988 Norovirus Phase 1/2 · NCT07198139 Completed

Also used in these trials (approved or third-party drugs, not COCP's own candidates): Velpatasvir And Sofosbuvir.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

COCP holds $2.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.4M/quarter from operations, an estimated runway of 2.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 79 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COCP files for a raise →

👥 Who Owns COCP

Insiders 32.7% Other 5%+ holders 44% Institutions (26 holders) 6% Public and other holders 17.3%
HolderTypeShares% of sharesAs of
OPKO HEALTH, INC. 5%+ holder (13D) 5,692,916 29.55% 2026-11-04
Phillip Frost, M.D. 5%+ holder (13D) 2,784,719 14.45% 2026-08-03
Steven D Rubin
Director · +16,410 options
Insider 2,660,242 13.81% 2024-10-09
Frost Phillip Md Et Al
Director, 10% owner · +744,041 options
Insider 2,020,651 10.49% 2026-08-05
Fred Hassan
Director · +735,836 options
Insider 1,383,009 7.18% 2025-10-28
Sam Lee
President and Co-CEO · +49,229 options
Insider 76,355 0.40% 2024-10-09
Roger D. Kornberg
Director · +24,615 options
Insider 67,878 0.35% 2024-10-09
James Joseph Martin
Co-CEO and CFO · +56,425 options
Insider 44,167 0.23% 2025-10-28
Richard C Jr Pfenniger
Director · +56,410 options
Insider 31,400 0.16% 2025-10-28
Anthony J Japour
Director · +16,410 options
Insider 14,924 0.08% 2024-10-09

Share count 19,264,893 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full COCP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COCP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.